Wegovy's effects on the liver: what the research shows and what to discuss with your doctor

You've been told you have fatty liver disease and you're wondering if Wegovy could help

It's a question our prescribers hear most weeks, and the honest starting point is that the evidence is moving quickly. Fatty liver disease ranges from simple steatosis (excess fat with minimal inflammation) through to MASH, where inflammation and scarring develop and can, over years, progress to cirrhosis. The connection to weight, metabolic health and insulin resistance means GLP-1 medicines like semaglutide have been studied in this context for several years.

What those studies showed was consistent enough for regulators to act. On 3 July 2026, the MHRA granted a conditional approval for semaglutide (Wegovy) to treat MASH in adults with moderate-to-advanced liver fibrosis, as announced on GOV.UK. This makes Wegovy the first medicine to hold a UK licence specifically for this indication. That is separate from its weight-management licence, but the two overlap significantly in practice: losing weight reduces liver fat, and semaglutide's appetite-regulating effect drives sustained calorie reduction over months rather than weeks.

The practical implication is that if you have fatty liver disease and your liver function has not deteriorated to the most severe stages, Wegovy may now be relevant to your care in a way it wasn't before 2026. That does not mean it is automatically right for your situation. The conditional approval covers a specific clinical population (adults with MASH and moderate-to-advanced fibrosis) and a prescriber will need to assess where on that spectrum you sit, what other medicines you take, and whether your liver function affects how semaglutide is processed. These are genuinely clinical questions, not administrative ones.

What is known, what is still being studied, and the limits of current evidence

The MASH approval gives the clinical picture a sharper outline, but some uncertainty remains worth naming honestly. The main Wegovy weight-management trials (including STEP 1, which reported around 15% average weight loss over 68 weeks at the 2.4mg maintenance dose) enrolled a broad population of adults with obesity but did not focus specifically on people with advanced liver disease. The NHS medicines information for semaglutide notes that semaglutide has not been extensively studied in people with severe hepatic impairment, and clinical guidance is cautious in that group.

For people with mild-to-moderate liver impairment (which is common in metabolic obesity) the available data suggest semaglutide is generally used without dose adjustment, but this is assessed individually. Liver enzymes, particularly ALT and AST, are sometimes monitored during treatment when there is existing liver disease, and your prescriber or specialist hepatologist will advise on how often.

What is well-established is the mechanism: semaglutide slows gastric emptying, reduces appetite, and drives sustained weight loss. Excess liver fat is almost always connected to caloric surplus and insulin resistance, so meaningful weight reduction tends to reduce hepatic steatosis measurably. Clinical data supporting the MASH indication showed reductions in liver inflammation and fibrosis scores in trial participants, not a guarantee of the same result for every individual, but a biologically coherent finding, and our page on Wegovy and the liver sets out the background behind that approval in detail. If you want to understand Wegovy's broader profile before a consultation, that context is useful.

Liver concerns alongside treatment: what to watch for and when to act

Wegovy's side-effect profile is led by gastrointestinal symptoms: nausea, loose stools, reflux, and reduced appetite, particularly in the first weeks after starting or after a dose step. For most people these settle. They matter more if you already have liver disease, because persistent vomiting or severe diarrhoea can cause dehydration that adds stress to already-compromised organ function. Staying well hydrated and reporting anything that feels severe to your prescriber is sensible, not alarmist.

The more specific signal to take seriously is acute pancreatitis. The MHRA's January 2026 Drug Safety Update highlighted this as a known but infrequent risk with GLP-1 medicines. Symptoms are severe, persistent stomach pain that may radiate toward the back, with or without vomiting, these warrant same-day medical assessment, not watchful waiting. Pancreatitis and liver disease can share overlapping symptoms, which is another reason to have a clinician involved if you are managing an existing hepatic condition.

Gallbladder problems are also noted on the GI-adjacent list: rapid weight loss of any cause can shift gallstone risk, and semaglutide has been associated with gallbladder events in some trials. If you develop pain in the upper right side of your abdomen, particularly after eating, tell your prescriber. For a fuller picture of how Wegovy affects the liver, including what the trial data showed about enzyme levels and fibrosis markers, our dedicated page covers the clinical background in more depth. If you are also curious about how semaglutide affects the liver at a mechanistic level, including what happens to liver fat and inflammation during treatment, that page explains the underlying science in detail.

Who to speak to, and what the consultation process looks like

If you have liver disease (diagnosed or suspected) the right route is a conversation that involves your GP or hepatologist as well as whoever prescribes Wegovy. The NHS England guidance on weight-management injections recommends informing your GP when starting private treatment, and that becomes especially important when there is an existing medical condition like liver disease. GP notification is part of how nume prescribes, our prescribers follow GPhC guidance on this as standard.

At nume, every consultation is personally read by a GPhC-registered Independent Prescriber on the same day, a real clinician, not an automated system. If your answers indicate liver disease or elevated liver function, the prescriber will either request more detail, recommend GP involvement before proceeding, or decline treatment where that is the safer course. That might not be the answer you were hoping for, but it is the right one. It is also worth knowing that Wegovy carries specific considerations for people who are pregnant or planning a pregnancy, and our page on semaglutide's effects on pregnancy explains what current guidance says. Similarly, if you have cardiovascular risk factors alongside liver disease, our page on Wegovy's effects on the heart outlines what the evidence shows. You can check your eligibility and start a free consultation to find out where you stand. If you have questions before that step, our support team can help point you in the right direction. The clinical approach we take means no consultation is rubber-stamped, which is exactly the standard a liver condition requires.